Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Trial Profile

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs UV 1 (Primary) ; Granulocyte macrophage colony stimulating factor; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Ultimovacs AS
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 23 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2019.
    • 23 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top